Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06368531
Other study ID # 2314270
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 4, 2024
Est. completion date August 15, 2025

Study information

Verified date April 2024
Source Odense University Hospital
Contact Henrik B Vaegter, PhD
Phone 004565413869
Email hbv@rsyd.dk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Insomnia is reported by more than 50% of patients with chronic pain. In this study, the investigators aim to advance the understanding of physiological sleep in individuals with chronic pain. To do this the investigators will monitor at-home sleep with an ear-EEG over 20 nights in patients with chronic pain and collect self-reported measures of sleep and pain. The collected data will be used to explore and characterize intra-individual variations in sleep metrics (e.g. total sleep time, time in each sleep stage (N1, N2, N3, REM), sleep latency, REM stage latency, wake after sleep onset, sleep efficiency, number of arousals and arousal index) over 20 nights.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date August 15, 2025
Est. primary completion date February 15, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: For a subject to be eligible, all inclusion criteria must be answered "yes": - Understand and write Danish. - Pain present on most days or every day during the past 3 months. - Pain limits daily activities or work on some days, most days or every day during the past 3 months. - Pain intensity equal to or larger than 4 on 0-10 Numeric Rating Scale [NRS] within the last week. - Informed consent obtained before any study related activities. Exclusion Criteria: For a subject to be eligible, all exclusion criteria must be answered "no": - Previous stroke or cerebral haemorrhage and any other structural cerebral disease. - Obstructive sleep apnoea (Defined as yes to 3 or more questions in the STOP-BANG questionnaire for women and 4 or more questions for men). - Teeth grinding (bruxism). - Pregnancy or lactation (Pregnancy is screened for through self-reporting as no risks regarding pregnancy have been identified for the described study procedures). - Narrow or malformed ear canals or piercings, making ear-EEG infeasible. - Allergic contact dermatitis caused by metals or generally prone to skin irritation. - People judged incapable, by the investigator, of understanding the participant instruction or who are not capable of carrying through the investigation.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Denmark Pain Center, Department of Anesthesiology and Intensive Care Medicine, University Hospital Odense Odense

Sponsors (3)

Lead Sponsor Collaborator
Odense University Hospital T&W Engineering A/S, University of Aarhus

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Sleep quality Sleep quality will be assessed with the Pittsburgh Sleep Quality Index (PSQI), which is developed to provide a reliable, valid and standardized measure of sleep quality. The PSQI consists of 19 items with 15 multiple choice questions and 4 open-ended questions. The 19 items form the basis a global score. The seven components evaluated by the PSQI are: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications and daytime dysfunction. Each component has a score ranging from 0 to 3 yielding a total score of 21, with higher scores reflecting worse sleep difficulties Baseline
Other Insomnia Insomnia will be assessed with the Insomnia Severity Index (ISI) which encompasses seven items measuring severity of sleep-onset; sleep maintenance and early morning awakening difficulties; satisfaction with sleep patterns; daily function interference; impairments due to sleep problems; and distress or concerns due to sleep problems. Each item is rated from 0 to 4 (0 = no problem, 4 = severe problem), yielding a total score of 28, with higher scores reflecting worse insomnia Baseline
Other The Graded Chronic Pain Scale Revised The Graded Chronic Pain Scale Revised (GCPS-R) is a brief, freely available questionnaire that assesses frequency and severity of pain and its impact. The GCPS-R uses 5 items to categorize pain into mild chronic pain, bothersome chronic pain, and high-impact chronic pain Baseline
Other Age Baseline
Other Sex Baseline
Other Ethnicity Baseline
Other Height Baseline
Other Weight Baseline
Other Level of education Baseline
Other Obstructive sleep apnea Risk for obstructive sleep apnea (OSA) will be evaluated with the snoring history, tired during the day, observed stop of breathing while sleeping, high blood pressure, BMI > 35 kg/m2 (or 30 kg/m2), age > 50 years, neck circumference > 40 cm and male gender) questionnaire (The STOP-BANG). The STOP-BANG questionnaire is a four item forced yes/no questionnaire. Baseline
Primary sleep period time (SPT) from Ear EEG Sleep metrics will be derived from the EEG assessments as recommended by the American Academy of Sleep Medicine (AASM). 5 nights every week for 4 weeks
Primary Qualitative sleep parameters obtained from sleep diary. Sleep diary is completed in the morning Sleep diary is completed 5 mornings every week for 4 weeks
Primary Pain intensity rating Average pain intensity during the last day and current pain intensity in the morning will be assessed on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain) Pain intensity rating is completed 5 mornings every week for 4 weeks
Primary Time from sleep onset until final awakening (TST) from Ear EEG Sleep metrics will be derived from the EEG assessments as recommended by the American Academy of Sleep Medicine (AASM). 5 nights every week for 4 weeks
Primary Sleep efficiency (SE) from Ear EEG Sleep metrics will be derived from the EEG assessments as recommended by the American Academy of Sleep Medicine (AASM). SE is the ratio of TST to time in bed / 100% 5 nights every week for 4 weeks
Primary Sleep onset latency (SOL) from Ear EEG Sleep metrics will be derived from the EEG assessments as recommended by the American Academy of Sleep Medicine (AASM). 5 nights every week for 4 weeks
Primary Wake after sleep onset (WASO) from Ear EEG Sleep metrics will be derived from the EEG assessments as recommended by the American Academy of Sleep Medicine (AASM). 5 nights every week for 4 weeks
Primary REM sleep latency from Ear EEG Sleep metrics will be derived from the EEG assessments as recommended by the American Academy of Sleep Medicine (AASM). 5 nights every week for 4 weeks
Primary Time from sleep onset until first epoch of REM stage sleep from Ear EEG Sleep metrics will be derived from the EEG assessments as recommended by the American Academy of Sleep Medicine (AASM). 5 nights every week for 4 weeks
Primary Amount of wake and stage N1, N2, N3, and R sleep as a percentage of SPT from Ear EEG Sleep metrics will be derived from the EEG assessments as recommended by the American Academy of Sleep Medicine (AASM). 5 nights every week for 4 weeks
Primary Number of awakenings within TST from Ear EEG Sleep metrics will be derived from the EEG assessments as recommended by the American Academy of Sleep Medicine (AASM). 5 nights every week for 4 weeks
Primary Arousal index which is number of arousals per hour from Ear EEG Sleep metrics will be derived from the EEG assessments as recommended by the American Academy of Sleep Medicine (AASM). 5 nights every week for 4 weeks
Secondary Ease-of-use and Comfort with ear EEG Three 0-10 questions are used: 1) How did you experience falling asleep with the ear EEG device, 2) How did you experience sleeping with the ear EEG device?, 3) How would you rate your experience of soreness or discomfort in your ears after sleeping with the device? A lower sum score is worse. Completed every morning after ear EEG first 2 weeks and at end of study
Secondary Adverse device effects Any adverse device effect defined as an adverse effect related to the use of the ear EEG Baseline, after 2 weeks, after 6 weeks
Secondary Polysomnography Polysomnography (PSG) is used in this study to ensure that the data that comes out of the automatic ear-EEG based sleep scoring matches the clinicians sleep scores based on the PSG. It will enable further development of the existing algorithm for automating the data analysis. Baseline
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
Completed NCT05036499 - PFI for Pain-Related Anxiety Among Hazardous Drinkers With Chronic Pain N/A